Zobrazeno 61 - 70
of 226
pro vyhledávání: '"Lorenzo Trippa"'
Publikováno v:
The Annals of Applied Statistics. 15
This paper presents a new modeling strategy for joint unsupervised analysis of multiple high-throughput biological studies. As in Multi-study Factor Analysis, our goals are to identify both common factors shared across studies and study-specific fact
Autor:
Jose Pablo Leone, Michael J. Hassett, Caroline Block, Sara M. Tolaney, Jiani Hu, Meredith Faggen, Lindsey Milisits, Ines Vaz-Luis, Adrienne G. Waks, Natalie Faye Sinclair, Michael Constantine, Frederick Briccetti, Kelly O'Neil, Lorenzo Trippa, Rebecca Rees, Nan Lin, Antonio Di Meglio, Harold J. Burstein, Eric P. Winer, Romualdo Barroso-Sousa, Ann H. Partridge
Publikováno v:
Journal of Clinical Oncology
PURPOSE The use of growth factors adds considerable expense and some toxicity to adjuvant breast cancer chemotherapy. We tested the feasibility and safety of omitting routine peg-filgrastim use during the paclitaxel portion of the dose-dense doxorubi
Autor:
Justin Cha, Cody J. Boehner, Nikhil C. Munshi, Romanos Sklavenitis-Pistofidis, Kwee Yong, Chip Stewart, Karma Salem, Eliezer M. Van Allen, Jihye Park, Yu-Tzu Tai, Andrew Dunford, Shankara Anand, Lorenzo Trippa, Amaro Taylor-Weiner, Jacob P. Laubach, Mark Bustoros, Benny Zhitomirsky, Robert A. Redd, Selina J Chavda, Irene M. Ghobrial, Shaji Kumar, Paul G. Richardson, Kenneth C. Anderson, François Aguet, Tarek H. Mouhieddine, P. Leif Bergsagel, Gad Getz, Mahshid Rahmat, Tineke Casneuf, Meletios A. Dimopoulos, Liudmila Elagina, Carl Jannes Neuse, Salomon Manier, Elizabeth A. Morgan, Ignaty Leshchiner, Efstathis Kastritis
Publikováno v:
J Clin Oncol
PURPOSE Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The disco
Publikováno v:
Biometrics. 77:587-598
Most statistical tests for treatment effects used in randomized clinical trials with survival outcomes are based on the proportional hazards assumption, which often fails in practice. Data from early exploratory studies may provide evidence of nonpro
Autor:
Robert A. Redd, Matthew Leventhal, Irene M. Ghobrial, Nikhil C. Munshi, Christopher J. Gibson, Jerome Ritz, Amin Nassar, Chip Stewart, Jihye Park, Romanos Sklavenitis-Pistofidis, Marzia Capelletti, Cody J. Boehner, David P. Steensma, Saud H. AlDubayan, Daniel Auclair, Lorenzo Trippa, Muhieddine M. Itani, Benjamin L. Ebert, Kalvis Hornburg, Shaadi Mehr, Mark Bustoros, Robert L. Schlossman, Henry Dumke, Jacob P. Laubach, Adam S. Sperling, Gad Getz, Salomon Manier, Paul G. Richardson, Eliezer M. Van Allen, Tarek H. Mouhieddine, Sabrin Tahri, Kenneth C. Anderson, Robert J. Soiffer, Daisy Huynh, Donna Neuberg, Brendan Reardon, Chia Jen Liu, Jonathan J Keats
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Nature Communications
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Nature Communications, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Nature Communications
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Nature Communications, 2020, 11 (1), pp.2996. ⟨10.1038/s41467-020-16805-5⟩
Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. The presence of somatic mutations in the peripheral blood is t
Autor:
Shyam K. Tanguturi, Rifaquat Rahman, Brian M. Alexander, Steffen Ventz, Daniel N. Cagney, Patrick Y. Wen, Shervin Tabrizi, Geoffrey Fell, Lorenzo Trippa
Publikováno v:
Neuro-Oncology
Background During the ongoing COVID-19 pandemic, contact with the health care system for cancer treatment can increase risk of infection and associated mortality. Treatment recommendations must consider this risk for elderly and vulnerable cancer pat
Publikováno v:
Journal of the American Statistical Association. 115:1689-1699
The positive relationship between airborne fine particulate matter (PM2.5) and cardiovascular disease (CVD) is established. Little is known about effect size heterogeneity across distinct CVD outco...
Autor:
Meng X He, Jake Conway, Eric P. Winer, Geoffrey I. Shapiro, Bose Kochupurakkal, Ricardo G. Pastorello, Chelsea Andrews, Lorenzo Trippa, Eliezer M. Van Allen, Robert Godin, Beth Overmoyer, Elizabeth A. Mittendorf, Rie K. Tahara, Wafa Osmani, Tanya Keenan, Jennifer L. Guerriero, Sara M. Tolaney, Grace Winship, Zhenying Tan-Wasielewski, Adam Tracy
Publikováno v:
Cancer Research. 80:P3-10
Introduction: mTNBC progresses rapidly on first-line chemotherapy. For instance, in the TNT trial, median progression-free survival (PFS) was 3 months on first-line carboplatin. Selective inhibition of Wee1, a negative regulator of the G2 cell cycle
Autor:
Lorenzo Trippa, Ann H. Partridge, Beth Overmoyer, Karla Helvie, Eric P. Winer, Chelsea Andrews, Sara M. Tolaney, Romualdo Barroso-Sousa, Arlindo R Ferreira, Nikhil Wagle, Rebecca Rees, Tianyu Li
Publikováno v:
Cancer Research. 80:P5-11
Background: For patients (pts) with HR+ /HER2- MBC, the optimal regimen following disease progression on the combination of a CDK4/6i plus endocrine therapy (ET) is unknown, and there is a need to evaluate whether continued CDK 4/6 blockade is benefi
Autor:
P. Kelly Marcom, Ann H. Partridge, Hope S. Rugo, Ron Bose, Denise A. Yardley, Douglas Weckstein, Katherine E. Reeder-Hayes, Harold J. Burstein, Michael Constantine, Rita Nanda, Jiani Hu, Patricia DeFusco, Nadine Tung, William T. Barry, Ian E. Krop, Chau T. Dang, Bhuvaneswari Ramaswamy, Frederick Briccetti, Vijayakrishna K. Gadi, V. Valero, Lorenzo Trippa, Sara M. Tolaney, Kit L. Cheng, Eric P. Winer, Antonio C. Wolff, Lowell L. Hart, Michelle Demeo, Blair Ardman, Steven J. Isakoff, Bryan P. Schneider, Kathryn J. Ruddy, Therese M. Mulvey, Rachel C. Jankowitz, Meredith Faggen, Dan Sayam Zuckerman, Kathy S. Albain, A. Merrill Garrett
Publikováno v:
Cancer Research. 80:P2-13
Background: CRA is a surrogate for ovarian toxicity and associated risk of infertility and long-term menopausal symptoms. Therefore, it is important to assess and report the rate of CRA when we study a new neoadjuvant treatment regimen. In the Adjuva